Use of statins in lower extremity artery disease: a review

BMC Surgery

Research Article

Lorenzo Chiariotti¹  Cinzia Perrino²  Marco Ferrone²  Bruno Trimarco²  Anna Sannino²  Roberto Corrado²  Giuseppe Giugliano²  Andreina Carbone²  Fernando Scudiero²  Raffaele Izzo²  Linda Brevetti²  Giovanni Esposito²  Giuseppe Gargiulo²  Federica Serino²  Gabriele Giacomo Schiattarella²  Bruno Amato³ 

[1] Department of Biology and Cellular and Molecular Pathology, Federico II University, via Pansini 5, 80131, Naples, Italy;Department of Clinical Medicine and Cardiovascular and Immunology Sciences, Federico II University, via Pansini 5, 80131, Naples, Italy;Department of General, Geriatric, Oncologic Surgery and Advanced Technologies, Federico II University, via Pansini 5, 80131, Naples, Italy;

关键词: Simvastatin;    Pravastatin;    Statin Therapy;    Pentoxifylline;    Cilostazol;   

DOI  :  10.1186/1471-2482-12-S1-S15

来源: Springer

【 摘 要 】

BackgroundLower extremity artery disease (LE-PAD) is one of the most common manifestations of atherosclerosis, particularly in elderly patients, and it is related to a high cardiovascular risk.DescriptionIt is well established that statin therapy is characterized by crucial benefits on cardiovascular system by limiting atherosclerotic progression and reducing cardiovascular events and mortality. A growing body of evidence support efficacy of statins in LE-PAD due to the ability of both reducing cardiovascular risk and improving walking distance and, hence, quality of life. Consequently, statin therapy should be considered in all LE-PAD patients and new LDL-cholesterol targets should be reached.ConclusionsOur opinion is that statin therapy remains still underutilized or with inadequate dosage, so therapy of LE-PAD patients should be improved to obtain all the demonstrated benefits of statins.

【 授权许可】

Unknown   
© Gargiulo et al; licensee BioMed Central Ltd. 2012. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.